Actively Recruiting
Dalpiciclib in HR+/HER2- ABC
Led by RenJi Hospital · Updated on 2026-02-03
103
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
CONDITIONS
Official Title
Dalpiciclib in HR+/HER2- ABC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed advanced breast cancer
- Hormone receptor-positive and human epidermal growth factor receptor 2-negative
- ECOG performance status of 0 or 1
You will not qualify if you...
- Pregnant or breastfeeding
- History of immunodeficiency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China, 200127
Actively Recruiting
Research Team
W
Wenjin Yin
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here